CVRx, Inc.
10900 73rd Avenue N.
Suite 116
Maple Grove
Minnesota
55369
United States
Tel: 763-416-2840
Fax: 763-416-2841
Website: http://www.cvrx.com/
99 articles about CVRx, Inc.
-
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
1/31/2024
CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company’s new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company’s Board.
-
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
1/25/2024
CVRx, Inc. (“CVRx”) today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook.
-
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
1/11/2024
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024.
-
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
1/8/2024
CVRx, Inc., a commercial-stage medical device company, announced certain preliminary unaudited fourth quarter and full year 2023 revenue results as well as its 2024 business outlook.
-
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/27/2023
CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024.
-
CVRx receives FDA approval for expanded labeling of BarostimU.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data
12/26/2023
CVRx, Inc. announced that the U.S. Food and Drug Administration has approved revised Instructions For Use for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial.
-
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
11/15/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.
-
CMS Increases Outpatient Payment for Barostim Procedure
11/3/2023
CVRx, Inc. announced that Centers for Medicare and Medicaid Services has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System final rule.
-
CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
10/12/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2023 financial and operating results after market close on Thursday, October 26th, 2023.
-
CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference
7/27/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023.
-
CVRx Reports Second Quarter 2023 Financial and Operating Results
7/25/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2023.
-
CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023
7/11/2023
CVRx, Inc. announced that it plans to release second quarter 2023 financial and operating results after market close on Tuesday, July 25th, 2023.
-
CVRx Set to Join Russell 2000 & 3000 Indexes
6/22/2023
CVRx, Inc. announced that it is set to join the Russell 2000 Index and the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.
-
CVRx to Present at the William Blair 43rd Annual Growth Stock Conference
5/25/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Thursday, June 8, 2023.
-
CVRx Reports First Quarter 2023 Financial and Operating Results
4/27/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2023.
-
CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023
4/20/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) today announced that it plans to release first quarter 2023 financial and operating results after market close on Thursday, April 27th, 2023.
-
Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure
3/21/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure (HF) Therapeutics (THT) conference on Tuesday, March 21, 2023.
-
CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
3/16/2023
CVRx, Inc. (“CVRx”) reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics (THT) conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston.
-
CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
1/26/2023
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) today announced its financial and operating results for the fourth quarter and full year of 2022, and provided a 2023 business outlook.
-
CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023
1/12/2023
CVRx, Inc. announced that it plans to release fourth quarter and full year 2022 financial and operating results after market close on Thursday, January 26, 2023.